Raymond James initiates Kymera Therapeutics stock coverage with outperform rating
Covered in this story
What has happened since
- Kymera Therapeutics Inc is down 0.8% since this was published, 4 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Raymond James’s $140 target on $KYMR is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Raymond James’s track record →Call it yourself
No member calls on $KYMR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Kymera Therapeutics Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.